Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Phathom Pharmaceuticals, Inc. - Common Stock (NQ: PHAT )

5.785 +0.065 (+1.14%)
Streaming Delayed Price Updated: 2:55 PM EST, Feb 19, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Phathom Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
Phathom Pharmaceuticals to Present at the Guggenheim Securities SMID Cap Biotech Conference
From Phathom Pharmaceuticals
Via GlobeNewswire
Top Biotech Short Squeeze Stocks
Investing in biotechnology stocks offers a unique opportunity for individuals looking to gain exposure to one of the most dynamic and innovative sectors of the market. 
Via Talk Markets
Topics Stocks / Equities
Phathom Pharmaceuticals Submits Citizen Petition to FDA Seeking Correction of Orange Book Listings for VOQUEZNA® (vonoprazan) Tablets
From Phathom Pharmaceuticals
Via GlobeNewswire
Phathom Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Updates
From Phathom Pharmaceuticals
Via GlobeNewswire
Preview: Phathom Pharmaceuticals's Earnings
Via Benzinga
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
From Phathom Pharmaceuticals
Via GlobeNewswire
Phathom Pharmaceuticals to Report Third Quarter 2024 Financial Results and Provide Business Update on Thursday, November 7, 2024
From Phathom Pharmaceuticals
Via GlobeNewswire
Phathom Pharmaceuticals to Present VOQUEZNA® Data at the American College of Gastroenterology (ACG) 2024 Annual Meeting
From Phathom Pharmaceuticals
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
From Phathom Pharmaceuticals
Via GlobeNewswire
These Are The Top 3 Most-Shorted Stocks In August 2024; Here’s Why
Short-squeeze opportunities are tough to find. Combine market timing with fundamentals for these stocks. 
Via Talk Markets
Phathom Pharmaceuticals Announces Pricing of $130 Million Offering of Common Stock and Pre-Funded Warrants
From Phathom Pharmaceuticals
Via GlobeNewswire
PHAT Stock Earnings: Phathom Pharmaceuticals Beats EPS, Beats Revenue for Q2 2024
PHAT stock results show that Phathom Pharmaceuticals beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
Phathom Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update
From Phathom Pharmaceuticals
Via GlobeNewswire
Phathom Pharmaceuticals Announces VOQUEZNA® (vonoprazan) Added to CVS Caremark Formularies for Commercially Insured Patients
From Phathom Pharmaceuticals
Via GlobeNewswire
Phathom Pharmaceuticals to Report Second Quarter 2024 Financial Results and Provide Business Update on Thursday, August 8, 2024
From Phathom Pharmaceuticals
Via GlobeNewswire
Phathom Pharmaceuticals Announces FDA Approval of VOQUEZNA® (vonoprazan) Tablets for the Relief of Heartburn Associated with Non-Erosive GERD in Adults
From Phathom Pharmaceuticals
Via GlobeNewswire
Ready for Quick Gains? 7 Top Short-Squeeze Stocks to Watch Now
Each of the following seven heavily-shorted stocks may have what it takes to become one of the next big short squeeze stocks. 
Via InvestorPlace
Ride the Gamma Wave: 3 Stocks on the Verge of a Short Squeeze
Though short squeezes are never guaranteed, these three potential short squeeze stocks could provide generous returns if bought right. 
Via InvestorPlace
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
From Phathom Pharmaceuticals
Via GlobeNewswire
Phathom Pharmaceuticals to Present VOQUEZNA® (vonoprazan) Data at DDW 2024 Annual Meeting
From Phathom Pharmaceuticals
Via GlobeNewswire
The 3 Best Healthcare Stocks to Buy in May 2024
Healthcare firms can make large amounts of money, particularly in the U.S. Here are the three best healthcare stocks to buy now. 
Via InvestorPlace
PHAT Stock Earnings: Phathom Pharmaceuticals Misses EPS, Misses Revenue for Q1 2024
PHAT stock results show that Phathom Pharmaceuticals missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024. 
Via InvestorPlace
Phathom Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update
From Phathom Pharmaceuticals
Via GlobeNewswire
Phathom Pharmaceuticals to Report First Quarter 2024 Financial Results and Provide Business Update on Thursday, May 9, 2024
From Phathom Pharmaceuticals
Via GlobeNewswire
Phathom Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare Conference
From Phathom Pharmaceuticals
Via GlobeNewswire
Phathom Pharmaceuticals Launches Direct-to-Consumer Campaign, “VOQUEZNA Can Kick Some Acid”
National TV and digital media campaign aims to motivate millions of people suffering from Erosive GERD to learn more about VOQUEZNA® (vonoprazan), the first and only FDA-approved potassium-competitive... 
From Phathom Pharmaceuticals
Via GlobeNewswire
PHAT Stock Earnings: Phathom Pharmaceuticals Misses EPS, Beats Revenue for Q4 2023
PHAT stock results show that Phathom Pharmaceuticals missed analyst estimates for earnings per share but beat on revenue for the fourth quarter of 2023. 
Via InvestorPlace
Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
From Phathom Pharmaceuticals
Via GlobeNewswire
Earnings Scheduled For March 7, 2024
Companies Reporting Before The Bell • CI&T (NYSE:CINT) is estimated to report quarterly earnings at $0.06 per share on revenue of $106.08 million. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.